KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Work In Process: 2018-2025

Historic Work In Process for Alnylam Pharmaceuticals (ALNY) over the last 7 years, with Sep 2025 value amounting to $35.5 million.

  • Alnylam Pharmaceuticals' Work In Process fell 49.18% to $35.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.5 million, marking a year-over-year decrease of 49.18%. This contributed to the annual value of $65.0 million for FY2024, which is 15.57% down from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Work In Process stood at $35.5 million for Q3 2025, which was down 18.90% from $43.8 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' Work In Process' 5-year high stood at $116.7 million during Q2 2023, with a 5-year trough of $23.6 million in Q1 2021.
  • In the last 3 years, Alnylam Pharmaceuticals' Work In Process had a median value of $69.9 million in 2024 and averaged $73.1 million.
  • In the last 5 years, Alnylam Pharmaceuticals' Work In Process soared by 525.07% in 2021 and then tumbled by 49.18% in 2025.
  • Alnylam Pharmaceuticals' Work In Process (Quarterly) stood at $100.9 million in 2021, then increased by 12.72% to $113.8 million in 2022, then tumbled by 32.36% to $77.0 million in 2023, then decreased by 15.57% to $65.0 million in 2024, then tumbled by 49.18% to $35.5 million in 2025.
  • Its Work In Process stands at $35.5 million for Q3 2025, versus $43.8 million for Q2 2025 and $54.0 million for Q1 2025.